Takeda’s Qdenga dengue vaccine approved for India, private rollout eyed in H1 2027
Qdenga is approved for people aged 4–60 and is expected to enter private healthcare channels in the first half of 2027. The two-dose dengue vaccine may initially be imported from Germany and is estimated to cost Rs 3,000–6,000 per dose.
What happened
India’s drug regulator approved Takeda’s Qdenga dengue vaccine. It is expected to launch through private healthcare settings in the first half of 2027,
Key facts
- Approved for individuals aged 4-60 years
- Two 0.5 ml doses administered three months apart
- 80.2% efficacy against confirmed dengue one year after second dose
- 90.4% efficacy against dengue-related hospitalisations after 18 months
- Expected price: Rs 3,000-6,000 per dose
- India reported 121,824 dengue cases and 131 deaths in 2025
Why this matters
Vaccine distributors, hospital chains and diagnostics players have an opening to pursue Takeda partnerships around private-channel reach, dengue-awareness programs and integrated prevention pathways before launch.
What to watch
- Final launch timing, import volumes and price by city and healthcare channel.
- Takeda's India supply-chain plan, including any local packaging, manufacturing or technology-transfer announcements.
- Physician guidance and real-world prescribing behavior for dengue-naive versus previously exposed patients.
- Private insurer reimbursement decisions and employer wellness-program adoption.
- Dengue incidence trends in 2026-2027 monsoon seasons, especially in major metros.
- Competitor vaccine approvals, domestic manufacturer programs and government immunization-policy signals.
- Completion rates for the second dose and reported adverse-event or public-confidence narratives.
- Build a phased launch around dengue-season calendars, beginning with high-incidence urban clusters and private hospital catchments.
- Secure pediatrician, general physician and infectious-disease specialist education to clarify eligibility, dosing intervals and patient selection.
- Create two-dose completion programs using app reminders, digital health records, pharmacy follow-up and bundled prepayment.
- Partner with premium pharmacy chains, hospital groups, diagnostic networks and travel-health clinics for vaccination access and lead generation.
- Test financing options, corporate vaccination packages and insurer conversations to reduce the upfront Rs 6,000-12,000 household expense.
- Prepare localized supply, cold-chain and inventory plans to reduce exposure to imported-product shortages, currency swings and long lead times.